Type 2 diabetes mellitus in the child and adolescent

Pediatric Diabetes

Volumn 9, Issue 5, 2008, Pages 512-526

  Rosenbloom, Arlan L ^a   Silverstein, Janet H ^a   Amemiya, Shin ^b   Zeitler, Phil ^c   Klingensmith, Georgeanna J ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c Children's Hospital Colorado   (United States)

^d CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BIGUANIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN MIMETIC; INSULIN; INSULIN GLARGINE; MEGLITINIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ALBUMINURIA; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BARIATRIC SURGERY; BEHAVIOR CHANGE; BLOOD GLUCOSE MONITORING; CHILD; CHILD HEALTH CARE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSENSUS DEVELOPMENT; COUGHING; DIABETES EDUCATION; DIABETIC DIET; DIABETIC HYPERTENSION; DIABETIC OBESITY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; EVENING DOSAGE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IMPOTENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RESISTANCE; KINESIOTHERAPY; LABORATORY TEST; LIFESTYLE MODIFICATION; LIVER TOXICITY; MATURITY ONSET DIABETES MELLITUS; METABOLIC SYNDROME X; MONOGENIC DISORDER; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WEIGHT GAIN; CLASSIFICATION; IMMUNOLOGY;

ADOLESCENT; AUTOIMMUNE DISEASES; CHILD; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 52649159745     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00429.x     Document Type: Article

References (98)

1. Rosenbloom AL, Joe JR, Young RS, Winter WE. The emerging epidemic of type 2 diabetes mellitus in youth. Diabetes Care 1999: 22: 345-354.
2. American Diabetes Association. Type 2 diabetes in children and adolescents: Consensus conference report. Diabetes Care 2000: 23: 381-389.
3. Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med 2006: 160: 523-528.
4. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005: 146: 693-700.
5. Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP. Type 2 diabetes in obese white children. Arch Dis Child 2002: 86: 207-208.
6. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr 1998: 37: 111-115.
7. Ehtisham S, Hattersley AT, Dunger DB, Barrett TG. First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child 2004: 89: 526-529.
8. The Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA 2007: 297: 2716-2724.
9. Kadiki OA, Reddy MR, Marzouk AA. Incidence of insulin-dependent diabetes (IDDM) and non-insulin-dependent diabetes (NLDDM) (0-34 years at onset) in Benghazi, Libya. Diabetes Res Clin Pract 1996: 32: 165-173.
10. Chan JC, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS. Obesity albuminuria, and hypertension among Hong Kong Chinese with non-insulin dependent diabetes mellitus (NIDDM). Postgrad Med J 1993: 69: 204-210.
11. Wei JN, Sung FC, Li CY et al. Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in Taiwan. Diabetes Care 2003: 26: 343-348.
12. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Type 2 diabetes in Asian-Indian urban children. Diabetes Care 2003: 26: 1022-1023.
13. Sayeed MA, Hunsain MZ, Banu A, Rurni MAK, Azad Khan AK. Prevalence of diabetes in a suburban population of Bangladesh. Diabetes Res CIin Pract 1997: 34: 149-155.
14. Braun B, Zimmerman MB, Kretchner N, Spatgo RM, Srnilh RM, Grdcey M. Risk factors for diabetes and cardiovascular disease in young Australian aborigines: A 5-year follow-up study. Diabetes Care 1996: 19: 472-479.
15. McGrath NM, Parker GN, Dawson P. Early presentation of type 2 diabetes mellitus in young New Zealand Maori. Diabetes Res Clin Pract 1999: 43: 205-209.
16. Eppens MC, Craig ME, Jones TW, Silink M, Ong S, Ping YJ, on behalf of the International Diabetes Federation Western Pacific Region Steering Committee. Type 2 diabetes in youth from the Western Pacific region: glycemic control, diabetes care and complications. Curr Med Res Opin 2006: 22: 1013-1020.
17. Sugihara S, Sasaki N, Kohno H et al. Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan. Clin Pediatr Endocrinol 2005: 14: 65-75.
18. Weiss R, Dufour S, Taksali SE et al. Prediabetes in obese youth: A syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003: 362: 951-957.
19. Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C. Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. J Clin Endocrinol Metab 2006: 91: 401-404.
20. Miller J, Silverstein JH, Rosenbloom AL. Type 2 diabetes in the child and adolescent. In: Lifshitz F, ed. Pediatric Endocrinology, 5th edn, volume 1. New York: Marcel Dekker, 2007: 169-188.
21. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998: 352: 837-853.
22. The STOPP-T2D Prevention Study Group. Presence of diabetes risk factors in a large US eighth-grade cohort. Diabetes Care 2006: 29: 212-217.
23. Kim C, McHugh C, Kwok Y, Smith A. Type 2 diabetes mellitus in Navajo adolescents. West J Med 1999: 170: 210-213.
24. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007: 369: 1823-1831.
25. Morales A, Rosenbloom AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. J Pediatr 2004: 144: 270-273.
26. Rosenbloom AL. Obesity, insulin resistance, beta cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. Diabetes Care 2003: 26: 2954-2956.
27. Turner R, Stratton I, Horton V et al. for the UK Prospective Diabetes Study (UKPDS) Group. UKPDS 25: Autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997: 350: 1288-1293.
28. Hathout EH, Thomas W, El-Shahawy et al. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 2001: 107: e102.
29. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 525-530.
30. Reinhard T, Schober E, Wiegand S, Thon A, Holl R, on behalf of the DPV-Weiss Study Group. β-cell autoantibodies in children with type 2 diabetes mellitus: Subgroup or misclassification? Arch Dis Child 2006: 91: 473-474, 77.
31. Landin-Olsson M. Latent autoimmune diabetes in adults. Ann N Y Acad Sci 2002: 958: 112-116.
32. Winter WE, Maclaren NK, Riley WJ, Clarke DW, Kappy MS, Spillar RP. Maturity onset diabetes of youth in black Americans. N Engl J Med 1987: 316: 285-291.
33. Banerji MA. Diabetes in African Americans: Unique pathophysiologic features. Curr Diab Rep 2004: 4: 219-223.
34. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006: 7: 352-360.
35. Gottlieb MS. Diabetes in offspring and siblings of juvenile- and maturity-onset-type diabetics. J Chronic Dis 1980: 33: 331-339.
36. Dahlquist G, Blom L, Tuvemo T, Nystrom L, Sandstrom A, Wall S. The Swedish childhood diabetes study - results from a nine year case register and a one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders. Diabetologia 1989: 32: 2-6.
37. Craig M, Hattersley A, Donaghue K. Definition, epidemiology, diagnosis and classification. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Pediatr Diabetes 2006: 7: 343-351.
38. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008: 31: S55-S60.
39. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO/NCD/NCS/99.2 1999.
40. Banerjee S, Raghavan S, Wasserman EJ, Linder BL, Saenger P, DiMartino-Nardi J. Hormonal findings in African American and Caribbean Hispanic girls with premature adrenarche: Implications for polycystic ovarian syndrome. Pediatrics 1998: 102: E35.
41. Ibañez L, Potau N, Marcos MV, de Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab 1999: 84: 4739-4741.
42. Plourde G. Impact of obesity on glucose and lipid profiles in adolescents at different age groups in relation to adulthood. BMC Fam Pract 2002: 3: 18 [http://www.biomedcentral.com/1471-2296/3/18].
43. Invitti C, Guzzaloni G, Gilardini L, Morbito F, Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care 2003: 26: 118-121, 24.
44. Tresaco B, Bueno G, Moreno A, Garagorri JM, Bueno M. Insulin resistance and impaired glucose tolerance in obese children and adolescents. J Physiol Biochem 2003: 59: 217-224.
45. Misra A, Vikram NK, Arya S et al. High prevalence of insulin resistance in postpubertal Asian Indian children is associated with adverse truncal body fat patterning, abdominal adiposity and excess body fat. Int J Obesity 2004: 28: 1217-1226.
46. Wabitsch M, Hauner H, Hertrampf M et al. Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany. Int J Obesity 2004: 28: 307-313.
47. Wiegand S, Maikowski U, Blankenstein O, Biebermann H, Tarnow P, Grüters A. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity -a problem that is no longer restricted to minority groups. Eur J Endocrinol 2004: 151: 199-206.
48. Shalitin S, Abrahami M, Lilos P, Phillip M. Insulin resistance and impaired glucose tolerance in obese children and adolescents referred to a tertiary care center in Israel. Int J Obes 2005: 29: 571-578.
49. Goran MI, Bergman RN, Avila Q et al. Impaired glucose tolerance and reduced β-cell function in overweight Latino children with a positive family history for type 2 diabetes. J Clin Endocrinol Metab 2004: 89: 207-212.
50. Lee S, Bacha F, Gungor N, Arslanian SA. Waist circumference is an independent predictor of insulin resistance in black and white youths. J Pediatr 2006: 148: 188-194.
51. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: The Bogalusa Heart Study. Pediatrics 2001: 108: 712-718.
52. Berenson GS, Srnivasan SR. Cardiovascular risk factors in youth with implications for aging: The Bogalusa Heart Study. Neurobiol Aging 2005: 26: 303-307.
53. Juonala M, Jarvisalo MJ, Maki-Torkko N, Kahonen M, Viikari JS, Raitakari OT. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: The Cardiovascular Risk in Young Finns Study. Circulation 2005: 112: 1486-1493.
54. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade Esystemic inflammation in overweight children. Pediatrics 2001: 107: e13.
55. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001: 138: 481-485.
56. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Community Study. N Engl J Med 2000: 342: 905-912.
57. Salomaa VV, Strandberg TE, Vanhanen H, Naukkarinen V, Sarna S, Miettinen TA. Glucose tolerance and blood pressure: Long-term follow-up in middle-age men. BMJ 1991: 302: 493-496.
58. Wierzbicki AS, Nimmo L, Feher MD, Cox A, Foxton J, Lant AF. Association of angiotensin-converting enzyme DD genotype with hypertension in diabetes. J Hum Hypertens 1995: 9: 671-673.
59. Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab 2001: 12: 225-230.
60. Laakso M. Lipids in type 2 diabetes. Semin Vasc Med 2002: 2: 59-66.
61. Goldberg IJ. Diabetic dyslipidemia: Causes and consequences. J Clin Endocrinol Metab 2001: 86: 965-971.
62. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001: 138: 38-44.
63. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007: 370: 685-697.
64. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000: 136: 727-733.
65. Smith JC, Field C, Braden DS, Gaymes CH, Kastner J. Coexisting health problems in obese children and adolescents that might require special treatment considerations. Clin Pediatr 1999: 38: 305-307.
66. Dietz WH, Gross WL, Kirkpatrick JA. Blount disease (tibia vara): Another skeletal disorder associated with childhood obesity. J Pediatr 1982: 101: 735-737.
67. Loder RT, Aronson DD, Greenfield ML. The epidemiology of bilateral slipped capital femoral epiphysis. A study of children in Michigan. J Bone Joint Surg 1993: 75: 1141-1147.
68. Poredos P. Endothelial dysfunction and cardiovascular disease. Pathophysiol Haemost Thromb 2002: 32: 274-277.
69. Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: A prospective study. Lancet 2001: 358: 1400-1404.
70. Eppens MC, Craig ME, Cusumano J et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006: 29: 1300-1306.
71. Kershnar AK, Daniels SR, Imperatore G et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Study. J Pediatr 2006: 149: 314-319.
72. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dohl-Jorgensen K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Microvascular and macrovascular complications. Pediatr Diabetes 2007: 8: 163-170.
73. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004: 329: 828.
74. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006: 354: 2443-2451.
75. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004: 292: 2585-2590.
76. Swift PG. Diabetes education. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Pediatr Diabetes 2007: 8: 103-109.
77. Delamater AM. Psychological care of children and adolescents with diabetes. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Pediatr Diabetes 2007: 8: 340-348.
78. Waldron S, Hanas R, Palmvig B. How do we educate young people to balance carbohydrate intake with adjustments of insulin? Horm Res 2002: 57 (Suppl. 1): 62-65.
79. Joe JR. Perceptions of diabetes by Indian adolescents. In: Joe JR, Young RS, eds. Diabetes as a Disease of Civilization: The Impact of Culture Change on Indigenous Peoples. Berlin: Mouton de Gruyter, 1994: 329-356.
80. Levine MD, Ringham RM, Kalarchian MA, Wisniewski L, Marcus MD. Is family based behavioral weight control appropriate for severe pediatric obesity? Int J Eat Disord 2001: 30: 318-328.
81. Aslander-van Vliet E, Smart C, Waldron S. Nutritional management in childhood and adolescent diabetes. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Pediatr Diabetes 2007: 8: 323-339.
82. Robinson TM. Reducing children's television viewing to prevent obesity. A randomized controlled trial. JAMA 1999: 82: 1561-1567.
83. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008: 371: 1073-1084.
84. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007: 298: 1180-1188.
85. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: A Meta-analysis. JAMA 2007: 298: 1189-1195.
86. Chiasson J, Josse R, Hunt J et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Int Med 1994: 121: 928-935.
87. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005: 27: 1500-1512.
88. Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr Res 2007: 62: 746-749.
89. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006: 29: 435-449.
90. Inge TH, Zeller M, Garcia VF, Daniels SR. Surgical approach to adolescent obesity. Adolesc Med Clin 2004: 15: 429-453.
91. Sjostrom L, Narbro K, Sjostrom D et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007: 357: 741-752.
92. Dixon JB, O'Brien PE, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. JAMA 2008: 299: 316-323.
93. Sackett DL, Holland WW. Controversy in detection of disease. Lancet 1965: 2: 357-359.
94. Urakami T, Morimoto S, Nitadori Y et al. Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res 2007: 61: 141-145.
95. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003: 157: 821-827.
96. Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002: 346: 393-403.
97. Urakami T, Owada M, Kitagawa T. Recent trend toward decrease in the incidence of childhood type 2 diabetes in Tokyo. Diabetes Care 2006: 29: 2176-2177.
98. Jeffrey RW. Community programs for obesity prevention: The Minnesota Heart Health Program. Obes Res 1995: 3 (Suppl 2): 283S-288S.